文献速递预防保健、筛查与疫苗妇女保健

高风险人乳头瘤病毒检测用于初级宫颈筛查:观察性研究

Primary cervical screening with high risk human papillomavirus testing: observational study.
PubMed 文献 · BMJ · 2019-02-06

该观察性研究比较了英格兰初级保健中 routine 高风险人乳头瘤病毒(hrHPV)检测与液基细胞学筛查的结局。578 547 名女性中 183 970 人(32%)接受 hrHPV 检测,基线 hrHPV 检测需约 80% 更多阴道镜检查,但检出更多宫颈上皮内瘤变;三年后 hrHPV 组宫颈上皮内瘤变 3 级或更差发生率极低,支持延长筛查间隔。

要点

  • 基线 hrHPV 检测较液基细胞学需约 80% 更多阴道镜检查(调整比值比 1.77,95%CI 1.73–1.82)。
  • hrHPV 检测检出宫颈上皮内瘤变 2 级或更差为液基细胞学的 1.49 倍(95%CI 1.43–1.55)。
  • 三年后 hrHPV 组宫颈上皮内瘤变 3 级或更差发生率极低(0.14,95%CI 0.09–0.23),支持延长筛查间隔。

核心结论

  • 在英格兰,常规初级 hrHPV 筛查较液基细胞学使宫颈上皮内瘤变 3 级或更差及宫颈癌检出分别增加约 40% 和 30%。
  • 三年后宫颈上皮内瘤变 3 级或更差发生率极低,支持延长筛查间隔。

研究设计与样本

  • 其中 183 970 人(32%)接受 hrHPV 检测,采用液基细胞学分流,hrHPV 阳性且细胞学阴性者接受两次早期召回。

主要发现

  • 基线 hrHPV 检测和早期召回需约 80% 更多阴道镜检查(调整比值比 1.77,95%CI 1.73–1.82)。
  • hrHPV 检测检出宫颈上皮内瘤变 2 级或更差为液基细胞学的 1.49 倍(95%CI 1.43–1.55),宫颈上皮内瘤变 3 级或更差为 1.44 倍(95%CI 1.36–1.51),宫颈癌为 1.27 倍(95%CI 0.99–1.63)。
  • 早期召回参与率和阴道镜转诊率分别为 80% 和 95%。
  • 发病率筛查时,hrHPV 组 33 506 人的宫颈上皮内瘤变 3 级或更差显著少于液基细胞学组 77 017 人(0.14,95%CI 0.09–0.23)。

临床怎么用

  • 基层医生应知晓 hrHPV 初筛可提高宫颈上皮内瘤变检出,但会增加阴道镜转诊负担。
  • 对 hrHPV 阳性且细胞学阴性者,两次早期召回的参与率约 80%,需加强随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide the first report on the main outcomes from the prevalence and incidence rounds of a large pilot of routine primary high risk human papillomavirus (hrHPV) testing in England, compared with contemporaneous primary liquid based cytology screening. DESIGN: Observational study. SETTING: The English Cervical Screening Programme. PARTICIPANTS: 578 547 women undergoing cervical screening in primary care between May 2013 and December 2014, with follow-up until May 2017; 183 970 (32%) were screened with hrHPV testing. INTERVENTIONS: Routine cervical screening with hrHPV testing with liquid based cytology triage and two early recalls for women who were hrHPV positive and cytology negative, following the national screening age and interval recommendations. MAIN OUTCOME MEASURES: Frequency of referral for a colposcopy; adherence to early recall; and relative detection of cervical intraepithelial neoplasia grade 2 or worse from hrHPV testing compared with liquid based cytology in two consecutive screening rounds. RESULTS: Baseline hrHPV testing and early recall required approximately 80% more colposcopies, (adjusted odds ratio 1.77, 95% confidence interval 1.73 to 1.82), but detected substantially more cervical intraepithelial neoplasia than liquid based cytology (1.49 for cervical intraepithelial neoplasia grade 2 or worse, 1.43 to 1.55; 1.44 for cervical intraepithelial neoplasia grade 3 or worse, 1.36 to 1.51) and for cervical cancer (1.27, 0.99 to 1.63). Attendance at early recall and colposcopy referral were 80% and 95%, respectively. At the incidence screen, the 33 506 women screened with hrHPV testing had substantially less cervical intraepithelial neoplasia grade 3 or worse than the 77 017 women screened with liquid based cytology (0.14, 0.09 to 0.23). CONCLUSIONS: In England, routine primary hrHPV screening increased the detection of cervical intraepithelial neoplasia grade 3 or worse and cervical cancer by approximately 40% and 30%, respectively, compared with liquid based cytology. The very low incidence of cervical intraepithelial neoplasia grade 3 or worse after three years supports extending the screening interval.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019. PMID: 30728133. doi:10.1136/bmj.l240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。